img

Global Pulmonary Fibrosis Drug Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pulmonary Fibrosis Drug Market Insights, Forecast to 2034

Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
Global Pulmonary Fibrosis Drug market is expected to reach to US$ 4543 million in 2024, with a positive growth of %, compared with US$ 4325 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Pulmonary Fibrosis Drug industry is evaluated to reach US$ 6088.1 million in 2029. The CAGR will be 5.0% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Pulmonary Fibrosis Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pulmonary Fibrosis Drug market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Boehringer Ingelheim
Roche
FibroGen, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
MediciNova, Inc.
Genentech, Inc.
Cipla Inc.
Biogen
Galapagos NV
Segment by Type
Pirfenidone
Nintedanib

Segment by Application


Hospital
Clinic

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Pulmonary Fibrosis Drug plant distribution, commercial date of Pulmonary Fibrosis Drug, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Pulmonary Fibrosis Drug introduction, etc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Pulmonary Fibrosis Drug
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Pulmonary Fibrosis Drug Product Introduction
1.2 Market by Type
1.2.1 Global Pulmonary Fibrosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Pirfenidone
1.2.3 Nintedanib
1.3 Market by Application
1.3.1 Global Pulmonary Fibrosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pulmonary Fibrosis Drug Sales Estimates and Forecasts 2018-2029
2.2 Global Pulmonary Fibrosis Drug Revenue by Region
2.2.1 Global Pulmonary Fibrosis Drug Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Pulmonary Fibrosis Drug Revenue by Region (2018-2024)
2.2.3 Global Pulmonary Fibrosis Drug Revenue by Region (2024-2029)
2.2.4 Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2029)
2.3 Global Pulmonary Fibrosis Drug Sales Estimates and Forecasts 2018-2029
2.4 Global Pulmonary Fibrosis Drug Sales by Region
2.4.1 Global Pulmonary Fibrosis Drug Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Pulmonary Fibrosis Drug Sales by Region (2018-2024)
2.4.3 Global Pulmonary Fibrosis Drug Sales by Region (2024-2029)
2.4.4 Global Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Pulmonary Fibrosis Drug Sales by Manufacturers
3.1.1 Global Pulmonary Fibrosis Drug Sales by Manufacturers (2018-2024)
3.1.2 Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Pulmonary Fibrosis Drug in 2022
3.2 Global Pulmonary Fibrosis Drug Revenue by Manufacturers
3.2.1 Global Pulmonary Fibrosis Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pulmonary Fibrosis Drug Revenue in 2022
3.3 Global Key Players of Pulmonary Fibrosis Drug, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Pulmonary Fibrosis Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pulmonary Fibrosis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pulmonary Fibrosis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Pulmonary Fibrosis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Pulmonary Fibrosis Drug Sales by Type
4.1.1 Global Pulmonary Fibrosis Drug Historical Sales by Type (2018-2024)
4.1.2 Global Pulmonary Fibrosis Drug Forecasted Sales by Type (2024-2029)
4.1.3 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
4.2 Global Pulmonary Fibrosis Drug Revenue by Type
4.2.1 Global Pulmonary Fibrosis Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Pulmonary Fibrosis Drug Forecasted Revenue by Type (2024-2029)
4.2.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
4.3 Global Pulmonary Fibrosis Drug Price by Type
4.3.1 Global Pulmonary Fibrosis Drug Price by Type (2018-2024)
4.3.2 Global Pulmonary Fibrosis Drug Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Pulmonary Fibrosis Drug Sales by Application
5.1.1 Global Pulmonary Fibrosis Drug Historical Sales by Application (2018-2024)
5.1.2 Global Pulmonary Fibrosis Drug Forecasted Sales by Application (2024-2029)
5.1.3 Global Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
5.2 Global Pulmonary Fibrosis Drug Revenue by Application
5.2.1 Global Pulmonary Fibrosis Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Pulmonary Fibrosis Drug Forecasted Revenue by Application (2024-2029)
5.2.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
5.3 Global Pulmonary Fibrosis Drug Price by Application
5.3.1 Global Pulmonary Fibrosis Drug Price by Application (2018-2024)
5.3.2 Global Pulmonary Fibrosis Drug Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Pulmonary Fibrosis Drug Market Size by Type
6.1.1 US & Canada Pulmonary Fibrosis Drug Sales by Type (2018-2029)
6.1.2 US & Canada Pulmonary Fibrosis Drug Revenue by Type (2018-2029)
6.2 US & Canada Pulmonary Fibrosis Drug Market Size by Application
6.2.1 US & Canada Pulmonary Fibrosis Drug Sales by Application (2018-2029)
6.2.2 US & Canada Pulmonary Fibrosis Drug Revenue by Application (2018-2029)
6.3 US & Canada Pulmonary Fibrosis Drug Market Size by Country
6.3.1 US & Canada Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Pulmonary Fibrosis Drug Sales by Country (2018-2029)
6.3.3 US & Canada Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Pulmonary Fibrosis Drug Market Size by Type
7.1.1 Europe Pulmonary Fibrosis Drug Sales by Type (2018-2029)
7.1.2 Europe Pulmonary Fibrosis Drug Revenue by Type (2018-2029)
7.2 Europe Pulmonary Fibrosis Drug Market Size by Application
7.2.1 Europe Pulmonary Fibrosis Drug Sales by Application (2018-2029)
7.2.2 Europe Pulmonary Fibrosis Drug Revenue by Application (2018-2029)
7.3 Europe Pulmonary Fibrosis Drug Market Size by Country
7.3.1 Europe Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Pulmonary Fibrosis Drug Sales by Country (2018-2029)
7.3.3 Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Pulmonary Fibrosis Drug Market Size
8.1.1 China Pulmonary Fibrosis Drug Sales (2018-2029)
8.1.2 China Pulmonary Fibrosis Drug Revenue (2018-2029)
8.2 China Pulmonary Fibrosis Drug Market Size by Application
8.2.1 China Pulmonary Fibrosis Drug Sales by Application (2018-2029)
8.2.2 China Pulmonary Fibrosis Drug Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Pulmonary Fibrosis Drug Market Size by Type
9.1.1 Asia Pulmonary Fibrosis Drug Sales by Type (2018-2029)
9.1.2 Asia Pulmonary Fibrosis Drug Revenue by Type (2018-2029)
9.2 Asia Pulmonary Fibrosis Drug Market Size by Application
9.2.1 Asia Pulmonary Fibrosis Drug Sales by Application (2018-2029)
9.2.2 Asia Pulmonary Fibrosis Drug Revenue by Application (2018-2029)
9.3 Asia Pulmonary Fibrosis Drug Sales by Region
9.3.1 Asia Pulmonary Fibrosis Drug Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Pulmonary Fibrosis Drug Revenue by Region (2018-2029)
9.3.3 Asia Pulmonary Fibrosis Drug Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Information
11.1.2 Boehringer Ingelheim Overview
11.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Boehringer Ingelheim Recent Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Overview
11.2.3 Roche Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Roche Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Roche Recent Developments
11.3 FibroGen, Inc.
11.3.1 FibroGen, Inc. Company Information
11.3.2 FibroGen, Inc. Overview
11.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 FibroGen, Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 FibroGen, Inc. Recent Developments
11.4 Merck & Co., Inc.
11.4.1 Merck & Co., Inc. Company Information
11.4.2 Merck & Co., Inc. Overview
11.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck & Co., Inc. Recent Developments
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Company Information
11.5.2 Bristol-Myers Squibb Company Overview
11.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bristol-Myers Squibb Company Recent Developments
11.6 MediciNova, Inc.
11.6.1 MediciNova, Inc. Company Information
11.6.2 MediciNova, Inc. Overview
11.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 MediciNova, Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 MediciNova, Inc. Recent Developments
11.7 Genentech, Inc.
11.7.1 Genentech, Inc. Company Information
11.7.2 Genentech, Inc. Overview
11.7.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Genentech, Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Genentech, Inc. Recent Developments
11.8 Cipla Inc.
11.8.1 Cipla Inc. Company Information
11.8.2 Cipla Inc. Overview
11.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Cipla Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Cipla Inc. Recent Developments
11.9 Biogen
11.9.1 Biogen Company Information
11.9.2 Biogen Overview
11.9.3 Biogen Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Biogen Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Biogen Recent Developments
11.10 Galapagos NV
11.10.1 Galapagos NV Company Information
11.10.2 Galapagos NV Overview
11.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Galapagos NV Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Galapagos NV Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Pulmonary Fibrosis Drug Industry Chain Analysis
12.2 Pulmonary Fibrosis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pulmonary Fibrosis Drug Production Mode & Process
12.4 Pulmonary Fibrosis Drug Sales and Marketing
12.4.1 Pulmonary Fibrosis Drug Sales Channels
12.4.2 Pulmonary Fibrosis Drug Distributors
12.5 Pulmonary Fibrosis Drug Customers
13 Market Dynamics
13.1 Pulmonary Fibrosis Drug Industry Trends
13.2 Pulmonary Fibrosis Drug Market Drivers
13.3 Pulmonary Fibrosis Drug Market Challenges
13.4 Pulmonary Fibrosis Drug Market Restraints
14 Key Findings in The Global Pulmonary Fibrosis Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pulmonary Fibrosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Pirfenidone
Table 3. Major Manufacturers of Nintedanib
Table 4. Global Pulmonary Fibrosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Pulmonary Fibrosis Drug Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Pulmonary Fibrosis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Pulmonary Fibrosis Drug Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2024)
Table 9. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2024-2029)
Table 10. Global Pulmonary Fibrosis Drug Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Pulmonary Fibrosis Drug Sales by Region (2018-2024) & (K Units)
Table 12. Global Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (K Units)
Table 13. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2024)
Table 14. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2024-2029)
Table 15. Global Pulmonary Fibrosis Drug Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Pulmonary Fibrosis Drug Sales Share by Manufacturers (2018-2024)
Table 17. Global Pulmonary Fibrosis Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Pulmonary Fibrosis Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Pulmonary Fibrosis Drug Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Pulmonary Fibrosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Pulmonary Fibrosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Fibrosis Drug as of 2022)
Table 23. Global Key Manufacturers of Pulmonary Fibrosis Drug, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Pulmonary Fibrosis Drug, Product Offered and Application
Table 25. Global Key Manufacturers of Pulmonary Fibrosis Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (K Units)
Table 28. Global Pulmonary Fibrosis Drug Sales by Type (2024-2029) & (K Units)
Table 29. Global Pulmonary Fibrosis Drug Sales Share by Type (2018-2024)
Table 30. Global Pulmonary Fibrosis Drug Sales Share by Type (2024-2029)
Table 31. Global Pulmonary Fibrosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Pulmonary Fibrosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Pulmonary Fibrosis Drug Revenue Share by Type (2018-2024)
Table 34. Global Pulmonary Fibrosis Drug Revenue Share by Type (2024-2029)
Table 35. Pulmonary Fibrosis Drug Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Pulmonary Fibrosis Drug Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (K Units)
Table 38. Global Pulmonary Fibrosis Drug Sales by Application (2024-2029) & (K Units)
Table 39. Global Pulmonary Fibrosis Drug Sales Share by Application (2018-2024)
Table 40. Global Pulmonary Fibrosis Drug Sales Share by Application (2024-2029)
Table 41. Global Pulmonary Fibrosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Pulmonary Fibrosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Pulmonary Fibrosis Drug Revenue Share by Application (2018-2024)
Table 44. Global Pulmonary Fibrosis Drug Revenue Share by Application (2024-2029)
Table 45. Pulmonary Fibrosis Drug Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Pulmonary Fibrosis Drug Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Pulmonary Fibrosis Drug Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Pulmonary Fibrosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Pulmonary Fibrosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Pulmonary Fibrosis Drug Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Pulmonary Fibrosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Pulmonary Fibrosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Pulmonary Fibrosis Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Pulmonary Fibrosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 60. Europe Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (K Units)
Table 61. Europe Pulmonary Fibrosis Drug Sales by Type (2024-2029) & (K Units)
Table 62. Europe Pulmonary Fibrosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Pulmonary Fibrosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (K Units)
Table 65. Europe Pulmonary Fibrosis Drug Sales by Application (2024-2029) & (K Units)
Table 66. Europe Pulmonary Fibrosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Pulmonary Fibrosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Pulmonary Fibrosis Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Pulmonary Fibrosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (K Units)
Table 72. Europe Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 73. China Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (K Units)
Table 74. China Pulmonary Fibrosis Drug Sales by Type (2024-2029) & (K Units)
Table 75. China Pulmonary Fibrosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Pulmonary Fibrosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (K Units)
Table 78. China Pulmonary Fibrosis Drug Sales by Application (2024-2029) & (K Units)
Table 79. China Pulmonary Fibrosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Pulmonary Fibrosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (K Units)
Table 82. Asia Pulmonary Fibrosis Drug Sales by Type (2024-2029) & (K Units)
Table 83. Asia Pulmonary Fibrosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Pulmonary Fibrosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (K Units)
Table 86. Asia Pulmonary Fibrosis Drug Sales by Application (2024-2029) & (K Units)
Table 87. Asia Pulmonary Fibrosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Pulmonary Fibrosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Pulmonary Fibrosis Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Pulmonary Fibrosis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Pulmonary Fibrosis Drug Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Pulmonary Fibrosis Drug Sales by Region (2018-2024) & (K Units)
Table 93. Asia Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 107. Boehringer Ingelheim Company Information
Table 108. Boehringer Ingelheim Description and Major Businesses
Table 109. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Boehringer Ingelheim Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Boehringer Ingelheim Recent Developments
Table 112. Roche Company Information
Table 113. Roche Description and Major Businesses
Table 114. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Roche Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Roche Recent Developments
Table 117. FibroGen, Inc. Company Information
Table 118. FibroGen, Inc. Description and Major Businesses
Table 119. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. FibroGen, Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. FibroGen, Inc. Recent Developments
Table 122. Merck & Co., Inc. Company Information
Table 123. Merck & Co., Inc. Description and Major Businesses
Table 124. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Merck & Co., Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Merck & Co., Inc. Recent Developments
Table 127. Bristol-Myers Squibb Company Company Information
Table 128. Bristol-Myers Squibb Company Description and Major Businesses
Table 129. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Bristol-Myers Squibb Company Recent Developments
Table 132. MediciNova, Inc. Company Information
Table 133. MediciNova, Inc. Description and Major Businesses
Table 134. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. MediciNova, Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. MediciNova, Inc. Recent Developments
Table 137. Genentech, Inc. Company Information
Table 138. Genentech, Inc. Description and Major Businesses
Table 139. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Genentech, Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Genentech, Inc. Recent Developments
Table 142. Cipla Inc. Company Information
Table 143. Cipla Inc. Description and Major Businesses
Table 144. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Cipla Inc. Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Cipla Inc. Recent Developments
Table 147. Biogen Company Information
Table 148. Biogen Description and Major Businesses
Table 149. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Biogen Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Biogen Recent Developments
Table 152. Galapagos NV Company Information
Table 153. Galapagos NV Description and Major Businesses
Table 154. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Galapagos NV Pulmonary Fibrosis Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Galapagos NV Recent Developments
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Pulmonary Fibrosis Drug Distributors List
Table 160. Pulmonary Fibrosis Drug Customers List
Table 161. Pulmonary Fibrosis Drug Market Trends
Table 162. Pulmonary Fibrosis Drug Market Drivers
Table 163. Pulmonary Fibrosis Drug Market Challenges
Table 164. Pulmonary Fibrosis Drug Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Fibrosis Drug Product Picture
Figure 2. Global Pulmonary Fibrosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Pulmonary Fibrosis Drug Market Share by Type in 2022 & 2029
Figure 4. Pirfenidone Product Picture
Figure 5. Nintedanib Product Picture
Figure 6. Global Pulmonary Fibrosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Pulmonary Fibrosis Drug Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Pulmonary Fibrosis Drug Report Years Considered
Figure 11. Global Pulmonary Fibrosis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Pulmonary Fibrosis Drug Revenue 2018-2029 (US$ Million)
Figure 13. Global Pulmonary Fibrosis Drug Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2018-2029)
Figure 15. Global Pulmonary Fibrosis Drug Sales 2018-2029 ((K Units)
Figure 16. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2018-2029)
Figure 17. US & Canada Pulmonary Fibrosis Drug Sales YoY (2018-2029) & (K Units)
Figure 18. US & Canada Pulmonary Fibrosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe Pulmonary Fibrosis Drug Sales YoY (2018-2029) & (K Units)
Figure 20. Europe Pulmonary Fibrosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China Pulmonary Fibrosis Drug Sales YoY (2018-2029) & (K Units)
Figure 22. China Pulmonary Fibrosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) Pulmonary Fibrosis Drug Sales YoY (2018-2029) & (K Units)
Figure 24. Asia (excluding China) Pulmonary Fibrosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales YoY (2018-2029) & (K Units)
Figure 26. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The Pulmonary Fibrosis Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Pulmonary Fibrosis Drug in the World: Market Share by Pulmonary Fibrosis Drug Revenue in 2022
Figure 29. Global Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
Figure 31. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
Figure 32. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
Figure 33. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
Figure 35. US & Canada Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
Figure 36. US & Canada Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
Figure 37. US & Canada Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada Pulmonary Fibrosis Drug Revenue Share by Country (2018-2029)
Figure 39. US & Canada Pulmonary Fibrosis Drug Sales Share by Country (2018-2029)
Figure 40. U.S. Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 41. Canada Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 42. Europe Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
Figure 43. Europe Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
Figure 44. Europe Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
Figure 45. Europe Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
Figure 46. Europe Pulmonary Fibrosis Drug Revenue Share by Country (2018-2029)
Figure 47. Europe Pulmonary Fibrosis Drug Sales Share by Country (2018-2029)
Figure 48. Germany Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 49. France Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 50. U.K. Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 51. Italy Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 52. Russia Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 53. China Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
Figure 54. China Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
Figure 55. China Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
Figure 56. China Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
Figure 57. Asia Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
Figure 58. Asia Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
Figure 59. Asia Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
Figure 60. Asia Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
Figure 61. Asia Pulmonary Fibrosis Drug Revenue Share by Region (2018-2029)
Figure 62. Asia Pulmonary Fibrosis Drug Sales Share by Region (2018-2029)
Figure 63. Japan Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 64. South Korea Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 65. China Taiwan Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 66. Southeast Asia Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 67. India Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 68. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales Market Share by Type (2018-2029)
Figure 69. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales Market Share by Application (2018-2029)
Figure 71. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Revenue Share by Country (2018-2029)
Figure 73. Middle East, Africa and Latin America Pulmonary Fibrosis Drug Sales Share by Country (2018-2029)
Figure 74. Brazil Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 75. Mexico Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 76. Turkey Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 77. Israel Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 78. GCC Countries Pulmonary Fibrosis Drug Revenue (2018-2029) & (US$ Million)
Figure 79. Pulmonary Fibrosis Drug Value Chain
Figure 80. Pulmonary Fibrosis Drug Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries